7th International Congress on Drug Therapy in HIV Infection (ICDTHI), 14-18 November 2004, Glasgow

29 March 2005. Related: Conference reports, Conference index, HIV 7th Glasgow 2004.

Reports from the conference

This popular European conference always includes some important studies.

Unless stated otherwise, all references in the following reports are to the Programme and Abstracts from the 7th International Congress on Drug Therapy in HIV Infection (7th ICDTHI), 14-18 November 2004, Glasgow, UK.

Abstracts from this meeting are posted to the excellent AEGiS conference database
www.aegis.org/conferences/hiv7

Oral Session abstracts such as PL1.1, PL5.1 are named PL1-1.html, PL5-1.html due to MSDOS/Windows file naming limitations. The poster abstracts are straight-forward—i.e. P1, P2, P300, etc are P1.html, P2.html, P300.html

The abstracts are also published as an eJournal of International AIDS Society (IAS), 2004.

The areas covered in this report are:

• Nandrolone decanoate combats HIV-related weight loss: results from three randomised studies

• Atazanavir boosts intracellular saquinavir levels: data on important new dual-boosted regimen

• Marked variability in plasma atazanavir levels: importance of ritonavir boosting and TDM

• Effective switching to atazanavir/ritonavir in clinical practice

• Ritonavir boosting may not overcome interaction between atazanavir and nevirapine

• Nevirapine associated adverse events in a cohort of pregnant women

• Higher nevirapine doses for children leads to better outcome

• TDM in Ugandan study highlights importance of refridgerated ritonavir

• Responses to TB treatment in HIV-positive and HIV-negative patients in the UK

• 800mg efavirenz may not be needed with rifampicin-based TB regimens, especially in African patients

• EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects

• Lower d4T dose maintains virologic suppression and CD4 increases